Despite the rare risk of blood clots, the vaccine suspension should be lifted, a council of the Centers for Disease Control said.
A US health board said Friday it was time to continue using Johnson & Johnson’s COVID-19 vaccine, despite the very rare risk. blood clots.
Recommendations from the Centers for Disease Control and Prevention (CDC) pave the way for J&J injections to begin to take effect again in the United States after regulators stopped using it last week to see A review of the rare but serious clot reports associated with low blood platelets.
The benefits of the vaccine outweigh that serious but small risk – especially against a virus that still infects tens of thousands of Americans every day, CDC advisers said. . The government will quickly consider that recommendation to decide on the next steps.
Top health officials said they hope to quickly return to using vaccines.
Dr. Beth Bell, a member of the advisory board and clinical professor at the department of global health at the University of Washington in Seattle, said: “The benefits clearly outweigh the risks from a population and fish perspective. multiply.
“It is a new risk. Admittedly it’s an incredibly small risk and much smaller than many other risks we choose to take on every day, ”she added.
Of the nearly eight million people vaccinated before the United States suspended J&J injections earlier this month, health officials discovered 15 cases of a very unusual type of blood clot, three of which dead. All are women, most younger than 50 years old.
The CDC and the Food and Drug Administration (FDA) initially found that six people developed such blood clots one to three weeks after getting J&J vaccinated, including one death. The investigation then expanded as the government received what Walensky called “a handful of” additional clot reports including a death that state officials said were under investigation in Oregon.
Reports of needles in haystacks have sparked alarm because European regulators have detected similarly rare blood clots in other COVID-19 vaccine recipients, from Oxford-AstraZeneca. The AstraZeneca and J&J photographs, though not identical, were taken with the same technology.
European scientists have found clues that an abnormal platelet-damaging immune response to the AstraZeneca vaccine could be the cause – and if so, doctors should avoid clot treatments. Most commonly, a blood-thinning drug called heparin.
That made the US authorities urgently suspend the J&J vaccination so they could let doctors know how to diagnose and treat these rare blood clots. Some patients were initially treated with heparin before anyone realized it could be more harmful than helping the patient.